Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (211-220 of 264) with videos related to

Pageof 27
Sort By:
Breast (Edinburgh, Scotland)|July 4, 2021
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterationsFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort StudyCarmine Valenza, Yue Zheng, Monica Milano, et al.
The Lancet. Oncology|May 21, 2021
Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trialJosé Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA TrialAntonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló, et al.
Breast Cancer Research : BCR|August 8, 2020
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancerLaura Biganzoli, Saverio Cinieri, Rossana Berardi, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Pegylated Liposomal Doxorubicin (Caelyx<sup>®</sup>) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II TrialSilvia Dellapasqua, Pamela Trillo Aliaga, Elisabetta Munzone, et al.
Breast Cancer Research and Treatment|October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Prudence A Francis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
Pageof 27

Showing results (211-220 of 264) with videos related to

Sort By:
Pageof 27
Breast (Edinburgh, Scotland)|July 4, 2021
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterationsFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Kathryn P Gray, Shari Gelber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast CancerIan Krop, Vandana Abramson, Marco Colleoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort StudyCarmine Valenza, Yue Zheng, Monica Milano, et al.
The Lancet. Oncology|May 21, 2021
Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trialJosé Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA TrialAntonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló, et al.
Breast Cancer Research : BCR|August 8, 2020
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancerLaura Biganzoli, Saverio Cinieri, Rossana Berardi, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Pegylated Liposomal Doxorubicin (Caelyx<sup>®</sup>) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II TrialSilvia Dellapasqua, Pamela Trillo Aliaga, Elisabetta Munzone, et al.
Breast Cancer Research and Treatment|October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Prudence A Francis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
Pageof 27